Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Ligand Pharmaceuticals Incorporated (LGND) had Consolidated Net Income/Loss of $48.51M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$63.69M |
|
$48.51M |
|
$3.21M |
|
$60.48M |
|
$55.10M |
|
$8.59M |
|
$55.71M |
|
$64.30M |
|
$52.55M |
|
$48.51M |
|
$48.51M |
|
|
Consolidated Net Income/Loss |
$48.51M |
$33.87M |
|
$8.59M |
|
$16.43M |
|
20.06M |
|
21.84M |
|
$2.42 |
|
$2.22 |
|
| Balance Sheet Financials | |
$1.46B |
|
-- |
|
$728.76M |
|
$2.19B |
|
$46.74M |
|
$1.13B |
|
$1.17B |
|
$1.22B |
|
$967.52M |
|
$656.73M |
|
$967.52M |
|
19.92M |
|
| Cash Flow Statement Financials | |
$72.71M |
|
$226.77M |
|
$532.30M |
|
$174.93M |
|
$1.01B |
|
$831.77M |
|
$24.25M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
31.18 |
|
-- |
|
-- |
|
0.54 |
|
1.16 |
|
94.95% |
|
13.49% |
|
13.49% |
|
-- |
|
100.96% |
|
76.16% |
|
$69.81M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
0.31 |
|
0.91 |
|
98.80 |
|
5.01% |
|
7.39% |
|
2.22% |
|
2.32% |
|
$48.57 |
|
$3.20 |
|
$3.33 |
|